Literature DB >> 33467021

Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease.

Francesca Assogna1, Claudio Liguori2,3, Luca Cravello4, Lucia Macchiusi1, Claudia Belli5, Fabio Placidi2,3, Mariangela Pierantozzi2, Alessandro Stefani2, Bruno Mercuri6, Francesca Izzi3, Carlo Caltagirone1, Nicola B Mercuri1,2,3, Francesco E Pontieri1,7, Gianfranco Spalletta1, Clelia Pellicano1.   

Abstract

A bstract : Rapid eye movement (REM) sleep behavior disorder (RBD) is a risk factor for developing Parkinson's disease (PD) and may represent its prodromal state. We compared neuropsychological and neuropsychiatric phenotypes of idiopathic (i) RBD, PD and healthy comparators (HC) in order to identify iRBD specific characteristics. Thirty-eight patients with iRBD, 38 PD patients with RBD (PD + RBD), 38 PD patients without RBD (PD-RBD) and 38 HC underwent a comprehensive neurological, neuropsychological and neuropsychiatric evaluation. iRBD, PD + RBD and PD-RBD performed worse than HC in short-term verbal memory, praxia, language and executive functions. iRBD had higher levels of anxiety, depression, apathy and alexithymia than HC. iRBD had higher levels of apathy than PD + RBD. Both PD groups had higher levels of anxiety and depression than HC. Surprisingly, iRBD performed better than all groups in long-term verbal memory. Patients diagnosed with iRBD are characterized by poor global cognitive performance, but better long-term memory and higher levels of depression, anxiety, alexithymia and apathy. Alexithymia and apathy in patients diagnosed with iRBD may be the expression of precocious derangement of emotional regulation, subsequently observed also in PD. Cognitive and neuropsychiatric symptoms of iRBD are early clinical manifestations of widespread neurodegeneration.

Entities:  

Keywords:  anxiety; depression; neurodegeneration; neuropsychiatry; risk factors

Year:  2021        PMID: 33467021      PMCID: PMC7830588          DOI: 10.3390/jpm11010051

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  50 in total

1.  National validation and proposed revision of REM sleep behavior disorder screening questionnaire (RBDSQ).

Authors:  Sara Marelli; Paola M V Rancoita; Federica Giarrusso; Andrea Galbiati; Marco Zucconi; Alessandro Oldani; Clelia Di Serio; Luigi Ferini-Strambi
Journal:  J Neurol       Date:  2016-09-26       Impact factor: 4.849

2.  Apathy in Parkinson's disease with REM sleep behavior disorder.

Authors:  Panagiotis Bargiotas; Maria Ntafouli; M Lenard Lachenmayer; Paul Krack; W M Michael Schüpbach; Claudio L A Bassetti
Journal:  J Neurol Sci       Date:  2019-02-20       Impact factor: 3.181

3.  Assessing whole brain perfusion changes in patients with REM sleep behavior disorder.

Authors:  S Mazza; J P Soucy; P Gravel; M Michaud; R Postuma; J Massicotte-Marquez; A Decary; J Montplaisir
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

4.  Cognitive performance in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease?

Authors:  Michele Terzaghi; Elena Sinforiani; Chiara Zucchella; Elena Zambrelli; Chiara Pasotti; Valter Rustioni; Raffaele Manni
Journal:  Sleep Med       Date:  2007-09-04       Impact factor: 3.492

5.  Severity of idiopathic rapid eye movement sleep behavior disorder correlates with depression and alexithymia.

Authors:  Hyo Jae Kim; Soo Jeong Kim; Sang-Ahm Lee
Journal:  Sleep Med       Date:  2020-06-06       Impact factor: 3.492

6.  Alexithymia associated with nightmare distress in idiopathic REM sleep behavior disorder.

Authors:  Isabelle Godin; Jaques Montplaisir; Jean-François Gagnon; Tore Nielsen
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

7.  Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease.

Authors:  Jean-François Gagnon; Mélanie Vendette; Ronald B Postuma; Catherine Desjardins; Jessica Massicotte-Marquez; Michel Panisset; Jacques Montplaisir
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

8.  Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.

Authors:  C H Schenck; J Y Montplaisir; B Frauscher; B Hogl; J-F Gagnon; R Postuma; K Sonka; P Jennum; M Partinen; I Arnulf; V Cochen de Cock; Y Dauvilliers; P-H Luppi; A Heidbreder; G Mayer; F Sixel-Döring; C Trenkwalder; M Unger; P Young; Y K Wing; L Ferini-Strambi; R Ferri; G Plazzi; M Zucconi; Y Inoue; A Iranzo; J Santamaria; C Bassetti; J C Möller; B F Boeve; Y Y Lai; M Pavlova; C Saper; P Schmidt; J M Siegel; C Singer; E St Louis; A Videnovic; W Oertel
Journal:  Sleep Med       Date:  2013-07-22       Impact factor: 4.842

9.  Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease.

Authors:  Michal Rolinski; Nahid Zokaei; Fahd Baig; Kathrin Giehl; Timothy Quinnell; Zenobia Zaiwalla; Clare E Mackay; Masud Husain; Michele T M Hu
Journal:  Brain       Date:  2015-11-18       Impact factor: 13.501

Review 10.  Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.

Authors:  Angie A Kehagia; Roger A Barker; Trevor W Robbins
Journal:  Neurodegener Dis       Date:  2012-10-03       Impact factor: 2.977

View more
  2 in total

1.  Comparative Study on Topological Properties of the Whole-Brain Functional Connectome in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease Without RBD.

Authors:  Shuai Chen; Sheng-Hui Wang; Ying-Ying Bai; Jie-Wen Zhang; Hong-Ju Zhang
Journal:  Front Aging Neurosci       Date:  2022-04-11       Impact factor: 5.702

2.  Abnormal Striatal-Cortical Networks Contribute to the Attention/Executive Function Deficits in Idiopathic REM Sleep Behavior Disorder: A Resting State Functional MRI Study.

Authors:  Hong-Ju Zhang; Sheng-Hui Wang; Ying-Ying Bai; Jie-Wen Zhang; Shuai Chen
Journal:  Front Aging Neurosci       Date:  2021-07-01       Impact factor: 5.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.